Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest
By Julie Steenhuysen
CHICAGO, July 30 (Reuters) -The benefit of Eisai 4523.T and Biogen's BIIB.O Alzheimer's drug Leqembi in patients with early-stage Alzheimer's appears to increase with continued use with no new safety issues, according to three-year data presented at an Alzheimer's meeting on Tuesday.
In the companies' pivotal clinical trial, Leqembi reduced cognitive decline by 27% after 18 months - data that supported the drug's approval last year.
The new study looked at how the drug performed in about 95% of trial patients who continued on the treatment. After three years, Leqembi slowed cognitive decline by 31% compared to what would be expected in similar patients who did not receive treatment.
There were no new safety findings over the three-year period. Brain swelling and bleeding associated with drugs that work by removing amyloid plaque from the brain largely occurred within the first six months of treatment, Dr. Christopher van Dyck, director of the Yale's Alzheimer's Disease Research Unit, told the meeting.
A separate analysis of data from a midstage study looked at patients who had a gap in treatment of 9 to 59 months following 18 months of initial treatment. In that study, there was still a difference, but once treatment stopped, the rate of cognitive decline reverted back to what was seen in patients on placebo.
Discontinuation of treatment also showed increases in Alzheimer's-related disease biomarkers, such as the return of amyloid plaques.
The findings were part of several presentations at the Alzheimer's Association International Conference in Philadelphia aimed at showing that Eisai's drug continues to benefit patients who stay on Leqembi after amyloid has been removed.
Eisai's drug targets protofibrils - toxic building blocks that eventually form clumps in the brain known as amyloid plaques, a hallmark of Alzheimer's disease. Leqembi both removes amyloid plaques and continues to target protofibrils, which can injure brain cells.
"There is no question long-term benefit is better than short-term benefit," Dr. Lynn Kramer, Eisai's chief clinical officer, told Reuters.
The studies underline differences between Eisai and Biogen's treatment and Eli Lilly's LLY.N Alzheimer's drug Kisunla (donanemab), which was approved on July 2.
The Lilly drug exclusively targets amyloid plaques. Once the brain plaque is gone, patients can discontinue treatment.
Reporting by Julie Steenhuysen
Editing by Bill Berkrot
Mga Kaugnay na Asset
Pinakabagong Balita
Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.
Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.
Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.
